254 related articles for article (PubMed ID: 21477091)
1. Comparative QSAR analyses of competitive CYP2C9 inhibitors using three-dimensional molecular descriptors.
Lather V; Fernandes MX
Chem Biol Drug Des; 2011 Jul; 78(1):112-23. PubMed ID: 21477091
[TBL] [Abstract][Full Text] [Related]
2. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Afzelius L; Zamora I; Masimirembwa CM; Karlén A; Andersson TB; Mecucci S; Baroni M; Cruciani G
J Med Chem; 2004 Feb; 47(4):907-14. PubMed ID: 14761192
[TBL] [Abstract][Full Text] [Related]
3. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
4. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors.
Roy K; Roy PP
Chem Biol Drug Des; 2008 Nov; 72(5):370-82. PubMed ID: 19012573
[TBL] [Abstract][Full Text] [Related]
5. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
6. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
7. Modeling the activity of furin inhibitors using artificial neural network.
Worachartcheewan A; Nantasenamat C; Naenna T; Isarankura-Na-Ayudhya C; Prachayasittikul V
Eur J Med Chem; 2009 Apr; 44(4):1664-73. PubMed ID: 18977558
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
9. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
10. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
11. 4D-fingerprints, universal QSAR and QSPR descriptors.
Senese CL; Duca J; Pan D; Hopfinger AJ; Tseng YJ
J Chem Inf Comput Sci; 2004; 44(5):1526-39. PubMed ID: 15446810
[TBL] [Abstract][Full Text] [Related]
12. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
Akula N; Lecanu L; Greeson J; Papadopoulos V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
[TBL] [Abstract][Full Text] [Related]
14. Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.
Saraceno M; Massarelli I; Imbriani M; James TL; Bianucci AM
Chem Biol Drug Des; 2011 Aug; 78(2):236-51. PubMed ID: 21575140
[TBL] [Abstract][Full Text] [Related]
15. Protein-based alignment in 3D-QSAR of FBPase inhibitors.
Yi P; Di YT; Liu W; Hao XJ; Ming Y; Huang DS; Yang J; Yi ZZ; Li ZJ; Yang RD; Zhang JC
Eur J Med Chem; 2011 Mar; 46(3):885-92. PubMed ID: 21269737
[TBL] [Abstract][Full Text] [Related]
16. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
17. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
18. Determination and prediction of xenoestrogens by recombinant yeast-based assay and QSAR.
Li F; Chen J; Wang Z; Li J; Qiao X
Chemosphere; 2009 Mar; 74(9):1152-7. PubMed ID: 19136139
[TBL] [Abstract][Full Text] [Related]
19. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]